Sign in
Taking people in United StatesPhase 2

Testing mogamulizumab to prevent adult T-cell leukemia in HTLV-1 carriers

Tests mogamulizumab in adults with HTLV-1 virus at higher risk of T-cell leukemia.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
Trial code
Registry title
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Status
Recruiting
Phase
Phase 2
People taking part
134 people, planned
Started
15 Nov 2024
Expected to end
15 Nov 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Mogamulizumab
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults carrying the HTLV-1 virus who are at high risk of developing adult T-cell leukemia/lymphoma (ATL) but do not have it yet. It tests whether mogamulizumab can prevent ATL.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Positive HTLV-1 antibody blood test and a high-risk profile (PVL of 8% of PBMC or more). People with a diagnosis of ATL cannot join.
Earlier treatment
No immunosuppressants or interferon alpha products within 6 months before enrolment. No other study drugs within 4 months. No multivitamins or supplements such as fucoidan, catechin or pentosan polysulfate within 2 weeks.
Biomarker or test result
Positive anti-HTLV-1 antibody in the serum and PVL of 8% of PBMC or more.

Main reasons for not taking part

  • Diagnosis of ATL
  • Pregnant, breastfeeding, or wishing to have children during treatment or within 3 months of the last dose
  • Positive hepatitis B or hepatitis C test (with some exceptions), or HIV positive unless HIV is well controlled
  • Active autoimmune disease that needed systemic treatment in the past 2 years
  • Serious complications such as heart failure, lung disease, renal failure, hepatic failure or uncontrolled diabetes

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Screening Cohort (US patients only):
  • Age ≥18 years when informed consent is obtained
  • Has freely given written informed consent to participate in the study; Treatment Cohorts (Cohorts 1 and 2):
  • Positive for anti-HTLV-1 antibody in the serum using an FDA approved assay for US patients (Avioq HTLV-I/II Microelisa System). UK patients should use UK Accreditation Service (UKAS) accredited tests, Abbot Architect ELISA Serology Screening assay and confirmatory serology Western Blot (performed at Public Health England, Virus Ref Dept, Colindale)
  • High-risk phenotype (PVL≥8% of PBMC)
  • Age ≥18 years when informed consent is obtained
  • Primary organ functions are stable; Neutrophil count: ≥ 1000/mm3, unless patient has diagnosis of ethnic neutropenia; Platelets: ≥100,000/mm3; Hemoglobin: ≥9.0 g/dL; Serum aspartate aminotransferase (AST): ≤1.5x upper limit of normal (ULN); Alanine aminotransferase (ALT): ≤1.5x ULN; Total bilirubin: ≤1.5x ULN; Serum creatinine (Cr): ≤1.5x ULN; Blood oxygen saturation (SpO2): ≥90%
  • Electrocardiogram (ECG): No abnormal findings requiring treatment are observed
  • Has freely given written informed consent to participate in the study
  • For females of reproductive potential: use of effective contraception during treatment and for at least 3 months after completion of mogamulizumab therapy. For males who have sexual intercourse with females of reproductive potential: use of effective contraception during treatment and for at least 3 months after completion of mogamulizumab therapy

Who cannot take part

  • In order to protect subjects and avoid any problems in evaluating the study drug, patients who meet any of the following criteria should be excluded from enrollment in the study, in either screening or treatment cohorts:
  • Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
  • Women who are pregnant, breastfeeding, who may be pregnant, or wish to bear children while receiving treatment or within 3 months of last dose of mogamulizumab
  • Patients who have taken multivitamins (Alinamin, vitamin C, etc.) or supplements such as fucoidan, catechin, and pentosan polysulfate within 2 weeks prior to the date of enrollment
  • Prior treatment with other study drugs within 4 months prior to giving informed consent
  • Serious complications (heart failure, lung disease, renal failure, hepatic failure, uncontrolled diabetes mellitus, etc.)
  • History of an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • Complications of spinal cord compressive lesions such as cervical spine disease, disc herniation, and ossification of the yellow ligament
  • Uncontrolled psychiatric disorder, epilepsy, or dementia
  • Positive test for Hepatitis B surface antigen or HBV-DNA (using real-time PCR). Positive Hepatitis B core antibody is permitted if HBV-DNA PCR is negative and the patient remains on prophylaxis during study
  • Positive test for Hepatitis C virus antibody, unless Hepatitis C PCR is negative
  • Positive test for HIV antibody, unless undetectable HIV RNA > 6 months and CD4 within normal limits per institutional standard
  • Patients with a history of any of the following:; Neutrophil count: ≤1000/mm3, unless patient has diagnosis of ethnic neutropenia; Acute or chronic hepatitis or hepatic cirrhosis, other than patients with positive antibodies and negative PCR as noted in criteria #11 and #12 below; Tuberculosis or with active tuberculosis; Myocardial infarction within 12 months prior to the date of enrollment; Allergic reaction to administration of antibody drug products; Other cancers. Patients with a history of a localized solid tumor who received definitive, curative treatment and who have been without evidence of disease for 5 years prior to enrollment will be able to enroll in the study. Patients with radically resected basal cell carcinoma of the skin, squamous cell carcinoma (except malignant melanoma), noninvasive cervix carcinoma, carcinoma in situ in the gastrointestinal tract or corpus of the uterus, localized thyroid cancer, and localized renal cell carcinoma will be able to enroll in the study if they are determined to be completely cured, even if within 5 years of enrollment
  • Any ailment that could be exacerbated by the administration of KW-0761, in the judgment of the Principal Investigator or co-Investigator
  • Diagnosis of ATL
  • Patients considered unqualified to participate in the study by the Principal Investigator or co-Investigator

Where in United States

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)Commack, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Steven Horwitz, MDTaking people
  • Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United StatesContact: Steven Horwitz, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.

The 2 groups in the trial

  • Cohort 1Treatment being tested

    Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses

    Treatment: Mogamulizumab

  • Cohort 2Treatment being tested

    Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

    Treatment: Mogamulizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2 Study for Screening and Prevention of Adult T-cell Leukemia/Lymphoma With Mogamulizumab in High-Risk Carriers of HTLV-1
Plain-language title
Testing mogamulizumab to prevent adult T-cell leukemia in HTLV-1 carriersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 March 2026